NASDAQ:BIIB

Biogen Stock Forecast, Price & News

$263.02
+0.22 (+0.08 %)
(As of 04/13/2021 12:03 PM ET)
Add
Compare
Today's Range
$263.02
Now: $263.02
$266.80
50-Day Range
$259.92
MA: $271.25
$284.63
52-Week Range
$223.25
Now: $263.02
$363.92
Volume9,956 shs
Average Volume1.27 million shs
Market Capitalization$40.07 billion
P/E Ratio8.71
Dividend YieldN/A
Beta0.53
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Biogen logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000
Employees9,100
Year Founded1978

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.38 billion
Cash Flow$36.84 per share
Book Value$73.93 per share

Profitability

Net Income$5.89 billion

Miscellaneous

Market Cap$40.07 billion
Next Earnings Date4/22/2021 (Confirmed)
OptionableOptionable

Headlines

Biogen (NASDAQ:BIIB) Given New $245.00 Price Target at Wedbush
April 12, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

80th out of 2,016 stocks

Biological Products, Except Diagnostic Industry

12th out of 177 stocks

Analyst Opinion: 3.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$263.02
+0.22 (+0.08 %)
(As of 04/13/2021 12:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biogen (NASDAQ:BIIB) Frequently Asked Questions

Is Biogen a buy right now?

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 sell ratings, 14 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Biogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
View analyst ratings for Biogen
or view top-rated stocks.

What stocks does MarketBeat like better than Biogen?

Wall Street analysts have given Biogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Thursday, April 22nd 2021.
View our earnings forecast for Biogen
.

How can I listen to Biogen's earnings call?

Biogen will be holding an earnings conference call on Thursday, April 22nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) issued its earnings results on Tuesday, February, 2nd. The biotechnology company reported $4.58 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $4.87 by $0.29. The biotechnology company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.80 billion. Biogen had a trailing twelve-month return on equity of 51.00% and a net margin of 35.63%. The firm's revenue for the quarter was down 22.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.34 EPS.
View Biogen's earnings history
.

How has Biogen's stock been impacted by Coronavirus (COVID-19)?

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BIIB stock has decreased by 10.2% and is now trading at $264.26.
View which stocks have been most impacted by COVID-19
.

How will Biogen's stock buyback program work?

Biogen announced that its Board of Directors has authorized a stock repurchase plan on Monday, December 23rd 2019, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company's management believes its stock is undervalued.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2021 Pre-Market earnings guidance on Wednesday, February, 3rd. The company provided earnings per share guidance of 17.00-18.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $24.67. The company issued revenue guidance of $10.45-10.75 billion, compared to the consensus revenue estimate of $11.22 billion.

What price target have analysts set for BIIB?

31 Wall Street analysts have issued 1 year price objectives for Biogen's stock. Their forecasts range from $175.00 to $450.00. On average, they anticipate Biogen's stock price to reach $303.59 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price.
View analysts' price targets for Biogen
or view top-rated stocks among Wall Street analysts.

Who are Biogen's key executives?

Biogen's management team includes the following people:
  • Mr. Michel Vounatsos, CEO & Director (Age 59, Pay $5.72M) (LinkedIn Profile)
  • Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 64, Pay $1.99M)
  • Dr. Alfred W. Sandrock Jr., Exec. VP of R&D (Age 63, Pay $1.87M)
  • Mr. Chirfi Guindo, Exec. VP of Global Product Strategy & Commercialization (Age 55, Pay $1.32M)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 57)
  • Ms. Robin C. Kramer, Sr. VP & Chief Accounting Officer (Age 55)
  • Mr. Mark J. Hernon, Sr. VP & Chief Information Officer (Age 57)
  • Mr. Michael Hencke, Director of Investor Relations
  • Ms. Natacha Gassenbach, Chief Communication Officer & Head of Corp. Affairs
  • Dr. Ginger Gregory, Exec. VP & Chief HR Officer (Age 53)

What is Michel Vounatsos' approval rating as Biogen's CEO?

186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among Biogen's employees.

Who are some of Biogen's key competitors?

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a number of institutional and retail investors. Top institutional investors include Saratoga Research & Investment Management (0.17%), Royal London Asset Management Ltd. (0.08%), State of Alaska Department of Revenue (0.04%), Pacer Advisors Inc. (0.02%), Calamos Advisors LLC (0.02%) and Hexavest Inc. (0.02%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michel Vounatsos and Stephen A Sherwin.
View institutional ownership trends for Biogen
.

Which institutional investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., State of Alaska Department of Revenue, OLD Dominion Capital Management Inc., Thomasville National Bank, CHICAGO TRUST Co NA, Pensionfund Sabic, Triangle Securities Wealth Management, and American Research & Management Co..
View insider buying and selling activity for Biogen
or view top insider-selling stocks.

Which institutional investors are buying Biogen stock?

BIIB stock was bought by a variety of institutional investors in the last quarter, including Saratoga Research & Investment Management, Royal London Asset Management Ltd., Everence Capital Management Inc., Pacer Advisors Inc., Calamos Advisors LLC, Pensionfund DSM Netherlands, Carroll Financial Associates Inc., and KMG Fiduciary Partners LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen
or or view top insider-buying stocks.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $264.26.

How much money does Biogen make?

Biogen has a market capitalization of $40.26 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis.

How many employees does Biogen have?

Biogen employs 9,100 workers across the globe.

Does Biogen have any subsidiaries?

The following companies are subsidiares of Biogen: AliveGen, Biogen (Argentina) SRL, Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (Denmark) Manufacturing ApS, Biogen (Denmark) New Manufacturing ApS, Biogen (RTP) Realty LLC, Biogen (Singapore) Pte Ltd, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd., Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Colombia S.A.S., Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding APS, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Hong Kong Limited, Biogen Idec Ltd., Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia SRL, Biogen Japan Ltd., Biogen Korea, Biogen Luxembourg Holding SARL, Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen Mexico Servicios S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o, Biogen Poland Sp. z.o.o, Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Ltd., Eidetica Biopharma GmbH, Fumapharm, Karyopharm Therapeutics, Nightstar Europa Limited, Nightstar Inc., Nightstar Limited, Nightstar Therapeutics, Nightstar Therapeutics Limited, Old Convergence Pharmaceuticals Ltd., Panion Ltd., Remedy Pharmaceuticals, Silver Acquisition Co. Ltd., Stromedix, Stromedix Inc., Syntonix Pharmaceuticals, Tungsten Bidco Limited, and Tysabri.

When was Biogen founded?

Biogen was founded in 1978.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

Where are Biogen's headquarters?

Biogen is headquartered at 225 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.